US-listed shares of biotechnology company Midatech Pharma (NASDAQ: MTP) have surged premarket after the company announced positive results from its Phase 1 study in patients with Diffuse Intrinsic Pontine Glioma (DIPG).
The primary endpoint of the study into Midatech’s MTX110 drug was to determine the dosage that will be used in Phase 2 trials in patients with DIPG.
The company said that seven patients were involved in the Phase 1 study and that three patients remain alive, although, survival was not an endpoint and there can be no conclusions drawn on the impact of the drug on survival rates.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“DIPG is a devastating pediatric brain cancer with limited treatment options and very poor outcomes. The overall survival data from this Phase I study are encouraging, although further study of MTX110 in DIPG is required to establish whether it can make a difference to these patients and their families,” said Steve Damment, Midatech’s Executive Vice President of R&D.
Midatech’s stock price is currently trading 37.50% higher premarket on Monday at $2.75 per share after Friday’s close at $2. Its London-listed shares have rallied 22% to 40.6p.
PEOPLE WHO READ THIS ALSO VIEWED:
